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Resistance of various pathogens toward quinolones has emerged as a serious threat to
combat infections. Analysis of plethora of genes and resistance mechanisms associated
with quinolone resistance reveals chromosome-borne and transferable determinants.
qnr genes have been found to be responsible for transferable quinolone resistance.
In the present work, a new allele qnrVC5 earlier reported in Vibrio fluvialis from this
laboratory was characterized in detail for its sequence, genetic context and propensity
to decrease the susceptibility for quinolones. The study has revealed persistence of
qnrVC5 in clinical isolates of V. fluvialis from Kolkata region through the years 2002–
2006. qnrVC5 existed in the form of a gene cassette with the open reading frame
being flanked by an upstream promoter and a downstream V. cholerae repeat region
suggestive of its superintegron origin. Sequence analysis of different qnrVC alleles
showed that qnrVC5 was closely related to qnrVC2 and qnrVC4 and these alleles
were associated with V. cholerae repeats. In contrast, qnrVC1, qnrVC3, and qnrVC6
belonging to another group were associated with V. parahaemolyticus repeats. The gene
manifested its activity in native V. fluvialis host as well as in Escherichia coli transformants
harboring it by elevating the MIC toward various quinolones by twofold to eightfold. In
combination with other quinolone resistance factors such as topoisomerase mutations
and aac(6’)-Ib-cr gene, qnrVC5 gene product contributed toward higher quinolone
resistance displayed by V. fluvialis isolates. Silencing of the gene using antisense peptide
nucleic acid sensitized the V. fluvialis parent isolates toward ciprofloxacin. Recombinant
QnrVC5 vividly demonstrated its role in conferring quinolone resistance. qnrVC5 gene,
its synergistic effect and global dissemination should be perceived as a menace for
quinolone-based therapies.
Keywords: gene cassettes, plasmids, superintegron, quinolone susceptibility
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INTRODUCTION
Vibrio fluvialis is known to cause severe cholera-like diarrhea
in humans and has been perceived as an emerging pathogen
(Bhattacharjee et al., 2010; Ramamurthy et al., 2014). Diarrheal
illnesses caused by this kind of bacteria are generally treated
using quinolone class of antibiotics. Increase in the reports of
emergence of multi drug resistant (MDR) V. fluvialis, showing
considerable resistance to quinolones has been a public health
concern (Srinivasan et al., 2006; Singh et al., 2012; Ramamurthy
et al., 2014). Reduced susceptibility to quinolones in bacteria
is mediated by factors such as mutations in the genes for
DNA gyrase and topoisomerase IV (the drug targets), eﬄux
activity, Qnr proteins and the inactivation of drug by quinolone-
modifying enzyme [AAC (6’) Ib-Cr; Bhardwaj et al., 2014;
Kim and Hooper, 2014]. The above mentioned mechanisms
may work alone or in combination. The synergistic action
of these mechanisms helps the pathogen to achieve higher-
level of resistance toward quinolones (Baranwal et al., 2002;
Srinivasan et al., 2006; Rushdy et al., 2013; Zhu et al.,
2013).
Qnr proteins are pentapeptide repeat proteins (PRPs)
which protect DNA gyrase from quinolone action (Tran and
Jacoby, 2002). qnr, a plasmid-mediated horizontally transferable
gene conferring quinolone resistance, was first discovered in
a plasmid from Klebsiella pneumoniae in 1998 (Martinez-
Martinez et al., 1998). Thereon, different variants of qnr genes
such as qnrA, qnrB, qnrC, qnrD, and qnrS were reported
in different pathogens from different parts of the world
(Strahilevitz et al., 2009). Chromosomal qnr-like genes such
as qnrVC, Ppqnr, Vpqnr, and Smqnr were also reported
from V. cholerae (Fonseca et al., 2008), Photobacterium
profundum (Poirel et al., 2005a), V. parahaemolyticus (Saga
et al., 2005), and Stenotrophomonas maltophilia (Sanchez et al.,
2008), respectively. Qnr proteins cause low-level resistance to
quinolones, facilitating the emergence of resistant mutants. In
combination with other mechanisms of quinolone resistance
such as topoisomerase mutations and eﬄux action, Qnr proteins
can help the pathogens to achieve clinical breakpoints of
quinolone resistance (Martinez-Martinez et al., 2003; Jeong et al.,
2008).
Till date, structures for PRPs such as MfpA, EfsQnr, QnrB1,
and AhQnr have been solved (Hegde et al., 2005, 2011; Vetting
et al., 2011; Xiong et al., 2011). QnrB1 (from K. pneumoniae) and
AhQnr (from Aeromonas hydrophila) possessed a right handed
quadrilateral β-helix, which is typical of PRPs and encompassed
coils with two loops (loop A and loop B) extending outward
from the regular structure, interrupting the β-helix turn. Unlike
the PRP structures of MfpA and EfsQnr from Gram-positive
bacteria Mycobacterium tuberculosis and Enterococcus faecalis,
respectively, QnrB1 and AhQnr possessed these two loops. It
was established that these two loops played a vital role in the
interaction of Qnr and DNA gyrase subunits (GyrA and GyrB;
Xiong et al., 2011). Loop A was found to interact with GyrA
“tower” whereas loop B was found to interact with GyrB TOPRIM
(Topoisomerase-Primase) domains. This also indicated that the
mechanisms of interaction of MfpA and EfsQnr with DNA
gyrase were different from that of QnrB1 and AhQnr. These
loops are found to be conserved among all plasmid-based Qnr
variants and some chromosome-borne Qnr proteins (Vetting
et al., 2011).
A former belief based on the mode of action of MfpA
and EfsQnr explains that Qnr protein binds with DNA gyrase
and prevents the formation of cleaved complex. Qnr protein
does not interact with the quinolones and therefore renders
resistance to drugs indirectly (Hegde et al., 2005, 2011). As the
structure of MfpA and EfsQnr varied from QnrB1 and AhQnr,
their mode of action should also principally vary. The model
proposed by Vetting et al. suggested that QnrB1 protein binds
to and destabilizes the topoisomerase-quinolone-DNA cleavage
complex, which eventually results in the release of quinolone and
religation of DNA. After this process, the Qnr protein would
be released and the active form of topoisomerase would be
regenerated (Vetting et al., 2011).
Emergence of transferable qnrVC alleles in Vibrionaceae
family and other bacterial species aggravated the hysteria on
quinolone resistance (Fonseca and Vicente, 2013; Pons et al.,
2013). So far, seven qnrVC alleles (named as qnrVC1 to qnrVC7)
have been reported from different parts of the globe1. These
alleles are found as gene cassettes, equipped with all the elements
necessary for their mobility, incorporation and expression such
as attC sites and their own cassette-specific promoter (Fonseca
and Vicente, 2013).
Previous studies from this laboratory have revealed the
presence of a qnrVC-like gene in the plasmids of three V. fluvialis
clinical isolates, BD146, L10734, and L9978 (Rajpara et al., 2009;
Singh et al., 2012) and this allele was named qnrVC5 by Fonseca
and Vicente in 2013 (Fonseca and Vicente, 2013). The plasmid
that harbored qnrVC5 in V. fluvialis BD146 also carried the
gene encoding trimethoprim resistance (dfrVI) and showed 99%
identity with pVN84 from V. cholerae O1 isolated from Vietnam
(Rajpara et al., 2009) and plasmid from V. parahaemolyticus V110
isolated from Hong Kong, China (Liu and Chen, 2013; Bhardwaj,
2015). The plasmid from V. parahaemolyticus V110 possessed
qnrVC5 allele whereas plasmid pVN84 carried qnrVC2, a non-
functional form of qnrVC5 due to the presence of several internal
stop codons (Fonseca et al., 2008; Fonseca and Vicente, 2013).
From the above discussion and other reports, it is amply clear
that qnrVC genes are disseminated globally and are likely to play
a vital role in quinolone resistance due to their wide dispersal
(Rajpara et al., 2009; Kim et al., 2010; Kumar and Thomas, 2011;
Fonseca and Vicente, 2013; Liu and Chen, 2013; Pons et al.,
2013; Bhardwaj, 2015). Since qnrVC5 allele was first reported
from this laboratory, it was of prime interest to decipher its role
in conferring resistance to quinolones. Therefore, the present
study was undertaken to understand the features of this gene/its
product in silico. Another focus of the study was to functionally
characterize QnrVC5 protein in native V. fluvialis host and
heterologous E. coli host. Results reflected the role of qnrVC5
in conferring resistance to quinolones and its synergy with other
quinolone resistance factors such as mutations in topoisomerase
genes and aac(6’) Ib-cr gene.
1http://www.lahey.org/qnrstudies/
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MATERIALS AND METHODS
Bacterial Strains and Plasmids
Clinical isolates of V. fluvialis BD146, L13828, L10734, L9978,
and L15318 were obtained from patients suffering from acute
cholera-like diarrhea admitted to The Infectious Diseases
Hospital, Kolkata during 2002–2006 (Kind gift from Dr. T.
Ramamurthy, National Institute of Cholera and Enteric Diseases,
Kolkata), and have been used in earlier studies (Rajpara et al.,
2009; Singh et al., 2012). Plasmid pET 28a (Novagen) was used
for expression of qnrVC5 gene. E. coli JM109 was used for
transformation experiments and E. coli BL21 (λDE3) was used
for recombinant protein expression studies.
In Silico Analysis
The DNA sequence analyses were done using BLAST tool
available at NCBI site2 and phylogenetic tree was constructed
using maximum-likelihood method in MEGA6 (Tamura et al.,
2013). Softberry-BPROM, a promoter prediction tool was used to
find the promoters and other regulatory elements in qnrVC5 gene
cassette3. The structure of QnrVC5 was predicted by I-TASSER
server using automated mode, as it employs hierarchical method
for protein structure and function prediction using multiple
threading approach based on structural templates from PDB
(Zhang, 2008; Roy et al., 2010, 2012).
Peptide Nucleic Acid (PNA)
The anti-qnrVC peptide-PNA [H-(KFF)3K-O-ccattttctagccct-
NH2] complementary to the region encompassing ribosomal
binding site and start codon of qnrVC5 gene was designed to
silence the qnrVC5 gene at RNA level. The PNA was conjugated
with cell penetrating peptide (KFF)3 to enhance the permeability
of this antisense oligonucleotide across the cell membrane of
bacteria (Good et al., 2001). The peptide-PNA was synthesized
by PANAGENE (Daejeon, South Korea) and the lyophilized PNA
oligomer was dissolved in sterile water as per manufacturer’s
instructions.
DNA Preparations
The preparations of genomic and plasmid DNA of V. fluvialis
were done as described earlier (Thungapathra et al., 2002).
Plasmid Mini kit or Maxi kit (Qiagen) was used for plasmid DNA
isolation according to the manufacturer’s instructions.
Polymerase Chain Reaction (PCR) and
Reverse Transcription PCR (RT-PCR)
Genomic DNA (200 ng) or plasmid DNA (10–50 ng) were
used as templates for PCR reactions. PCR reactions were
performed using the protocol described earlier (Singh et al.,
2012). Primers used for PCR experiments were qnrVC-F
5′-CGCGGATCCATGGATAAAACAGACCAG-3′ and qnrVC-
R 5′-CCGCTCGAGTTAGTCAGGAACTACTAT-3′. These
2http://blast.ncbi.nlm.nih.gov/Blast.cgi
3http://linux1.softberry.com/berry.phtml?topic=bprom&group=programs&
subgroup=gfindb
primers incorporated sites (in bold) for BamHI and XhoI
restriction enzymes that were used for cloning in the expression
vector pET28a. Primers used to amplify the entire qnrVC5
gene cassette, encompassing the upstream and downstream
sequences along with coding region, were qnrVCcas-F
5′-CGTATAGAAAGCGTTATGTG-3′ and qnrVCcas-R 5′-
CTGCTGCCATAATGGATAT-3′. Each PCR consisted of
an initial denaturation at 94◦C for 5 min, followed by 30
amplification cycles, each involving an initial denaturation at
94◦C for 0.5 min followed by annealing and extension steps.
Annealing condition for qnrVC-F and qnrVC-R primer pair was
65◦C for 0.5 min, and for qnrVCcas-F and qnrVCcas-R primer
pair was 60◦C for 0.5 min. For both the above reactions, extension
was performed at 72◦C for 1 min and final polymerization was
carried out at 72◦C for 10 min. Taq polymerase (Fermentas)
was used and reactions were performed in T100 thermal cycler
(Bio-Rad Laboratories). Purification of PCR products was
performed using QIA-quick PCR purification kit (Qiagen) as per
the manufacturer’s instructions.
RT-PCR was carried out to confirm the expression of qnrVC5
gene and aac(6’) Ib-cr gene in the native isolates of V. fluvialis
and their E. coli JM109 transformants. Total RNA was isolated
from V. fluvialis isolates and their E. coli transformants, using
RNeasy bacteria mini kit (Qiagen) as per the manufacturer’s
instructions. The protocol consisted of growing the cultures in LB
medium followed by treatment with lysozyme and proteinase K
for cell lysis and RNA was purified from the lysate using RNeasy
mini spin columns. The RNA preparations were subsequently
treated with DNaseI (Fermentas) to remove the genomic DNA
contamination. RT-PCR was carried out using Qiagen one step
RT-PCR kit following manufacturer’s instructions. Each RT-PCR
reaction mixture consisted of 10 µl of 5X Qiagen 1-step RT-
PCR buffer, 2.0 µl of dNTP mix containing 2.5 mM of each
dNTP, 50.0 pmol of each primer, 2.0 µl of Qiagen 1-step RT-PCR
enzyme mix and RNase free water to a final volume of 49.0 µl.
The 1.0 µl template RNA (0.1 µg µl−1) was added to make the
final reaction volume of 50.0 µl. The primer pair qnrVC-F and
qnrVC-R, mentioned above, were used for RT-PCR of qnrVC5
transcripts, whereas AG-F 5′- TGACCAACTGCAACGATTCC -
3′ and AG-R 5′- ACCCATAGAGCATCGCAAGGT -3′ were used
for RT-PCR of aac(6’)Ib-cr transcripts. Each RT-PCR experiment
consisted of reverse transcription step at 50◦C for 30 min and
an initial denaturation at 95◦C for 15 min, followed by 30
amplification cycles, each consisting of a denaturation step at
94◦C for 0.5 min followed by annealing and extension steps.
The annealing condition for qnrVC5 amplification was 60◦C
for 0.5 min and for aac(6’) Ib-cr amplification was 64◦C for
0.5 min. Extension was performed at 72◦C for 1 min and final
polymerization was carried out at 72◦C for 10 min. The reactions
were performed in T100 thermal cycler (Bio-Rad Laboratories).
Gene Cloning and Protein Expression
Vector pET28a and the amplicon of qnrVC5 (from V. fluvialis
BD146) each were separately double-digested with BamHI and
XhoI. Subsequent to digestion, the dephosphorylated vector
and qnrVC5 insert were ligated, the ligation mixture was
electroporated in E. coli JM109 cells and the transformed cells
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were plated on LB plates containing kanamycin (50 µg ml−1)
to obtain the recombinants. Expression of QnrVC5 protein was
studied by induction of E. coli BL21 (λDE3) cells harboring the
recombinant clones with 1mM IPTG for 2 h at 37◦C, followed
by SDS-PAGE analysis of total cell lysates. The protein band
corresponding to QnrVC5 was excised from the gel and subjected
to trypsin digestion. The authenticity of this protein was then
confirmed by peptide mass fingerprinting on Bruker Ultraflex III
MALDI instrument. The protein identification was done through
Mascot software.
Minimum Inhibitory Concentration (MIC)
Assays
Twofold dilution method was used to determine the MIC of
various quinolones for native V. fluvialis clinical isolates, E. coli
transformants and QnrVC5 recombinant as described previously
with minor modifications described below (Mohanty et al., 2012).
(i) MIC assay for native V. fluvialis clinical isolates and
their E. coli JM109 transformants
Overnight grown colonies of V. fluvialis were inoculated in
5 ml LB and grown at 37◦C till the optical density at 600 nm
reached 0.1. This culture was used as inoculum for MIC assay.
Concentration of the test drug was diluted twofold in Muller
Hinton Broth (MHB). Fifty microliters of inoculum was added
to 2 ml of each drug concentration in a 24-well cell culture plate
and incubated at 37◦C for 18 h. MIC was read as the lowest
concentration of the drug where no growth was observed. The
assays were repeated at least three times. The MIC of E. coli
JM109 transformants (obtained from the plasmid preparation
derived from the native V. fluvialis host) was determined by the
same method except that the transformants were selected in LB
medium containing ampicillin (25 µg ml−1) before inoculating
into the MIC assay plate.
(ii) MIC assay for QnrVC5 recombinants
The recombinant plasmid was transformed into E. coli BL21
(λDE3) cells and the transformants were selected on LB agar
containing kanamycin (50 µg ml−1). E. coli BL21 (λDE3)
cells carrying vector pET28a was used as a control. Both the
recombinant and the control were induced with 1mM IPTG for
2 h. Subsequently, the induced cultures were adjusted to the
optical density of 0.1 at 600 nm and used as inoculum for MIC
assays. The concentration of the test drug was diluted twofold in
MHB containing kanamycin (50 µg ml−1) and IPTG (1 mM).
Fifty microliters of inoculum was added to 2 ml of each drug
concentration in a 24-well cell culture plate and incubated at 37◦C
for 18 h to determine the MIC value as described above. The
assays were repeated at least three times.
(iii) MIC assay for V. fluvialis isolates in presence of
PNA
MIC of ciprofloxacin was determined for V. fluvialis isolates
(BD146, L10734, L9978, and L15318) using the same twofold
dilution method described above, but in a 96-well polypropylene
plate in a total assay volume of 100 µl with 5 µl of cultures as
inoculum. The effect of PNA in reducing the MIC of ciprofloxacin
was tested as described previously (Jeon and Zhang, 2009). The
assay was initially done with V. fluvialis BD146 to check the
effect on MIC with increasing concentrations of PNA (0, 2, 4, and
6 µM). Subsequent to that, assays were performed without and
with PNA (4 µM) for all the above mentioned V. fluvialis isolates.
Mutant Prevention Concentration (MPC)
Assay
Mutant prevention concentration assay was performed as
described previously with minor modifications (Marcusson et al.,
2005). Hundred microliters of overnight grown culture of each
of the V. fluvialis isolates (BD146, L15318, L10734, L9978, and
L13828) was inoculated in 25 ml LB and grown at 37◦C until
the optical density at 600 nm reached 1.0 (∼109 cells/ml). The
culture was centrifuged at 8000 rpm for 5 min and the pellet
was resuspended in LB to contain ≥ 1010 cells/ml. Subsequently,
200 µl of resuspended culture was spread on the Muller
Hinton Agar (MHA) plates containing defined concentrations of
ciprofloxacin. Each strain was tested with six concentrations of
ciprofloxacin starting from their MIC (i.e., 1X, 2X, 4X, 8X, 16X,
32X MIC). The plates were incubated at 37◦C for 96 h and MPC
was recorded as the lowest concentration of ciprofloxacin that
prevented the emergence of mutant colonies. The assays were
individually performed three times.
RESULTS
Presence of qnrVC5 Gene in V. fluvialis
Isolates, Characterization of the Gene,
and its Flanking Genetic Environment
The plasmid pBD146 (GenBank accession no. EU574928)
obtained from a clinical isolate of V. fluvialis BD146, 2002, was
earlier reported to harbor a qnr gene (GenBank accession no.
JN408080; Rajpara et al., 2009). In another report, the same gene
was also found in plasmid preparations from two V. fluvialis
isolates L10734 (GenBank accession no. JN571550) and L9978
(GenBank accession no. JN571549; Singh et al., 2012) and termed
as qnrVC-like gene. Later, it was named qnrVC5 allele (Fonseca
and Vicente, 2013). The sequence encoded a protein of 218 amino
acids with two domains of 11 and 32 pentapeptide repeats bridged
by a glycine residue.
Based on the sequence of pBD146, it was evident that qnrVC5
gene in V. fluvialis isolate BD146 was present in the form of
a gene cassette where ORF was flanked with a downstream
recombination site corresponding to V. cholerae repeat (VCR)
region and an upstream internal promoter (PqnrVC) with
canonical sequence (Figure 1A). Most interestingly, upstream
of –10 and –35 sequences of the PqnrVC promoter, binding sites
for PurR (purine metabolism repressor) and ArgR2 (arginine
metabolism regulator) were also predicted in this cassette
using Softberry – BPROM online tool (Figure 1A). To further
characterize the gene sequence from other two isolates (L10734
and L9978), primers qnrVCcas-F and qnrVCcas-R were designed
based on the sequence flanking qnrVC5 in pBD146. PCR carried
out using these primers revealed that the same length of gene
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FIGURE 1 | The genetic environment, homology and structure prediction of the gene/gene product of qnrVC5 gene from V. fluvialis isolate BD146.
(A) The structure of qnrVC5 gene cassette in pBD146 with canonical promoter sequence and VCR recombination site, at the upstream and downstream positions of
the coding region, respectively. (B) Dendrogram of qnrVC5 allele with other qnrVC alleles, showing the close relationship of qnrVC5 with qnrVC2 and qnrVC4.
(C) Structure prediction of QnrVC5 using I-TASSER server, showing right handed quadrilateral β-helix forming 10 coils, interrupted by two loops.
cassette was also amplified from these two isolates suggestive of
the similar gene organization in these three bacterial isolates.
Sequence Analysis, Homology, and
Structure Prediction for qnrVC5
Gene/Protein
At nucleotide level, the ORF of qnrVC5 allele shared 99% identity
with qnrVC4 and qnrVC2, and 97% identity with qnrVC7.
qnrVC5 sequence was found to have 76% identity with qnrVC1
and 75% with both qnrVC3 and qnrVC6 alleles. The phylogenetic
tree for all these qnrVC genes showed that qnrVC1, qnrVC3, and
qnrVC6 belonged to the same group, whereas qnrVC2, qnrVC4,
qnrVC5, and qnrVC7 formed another group (Figure 1B). This
clearly showed that qnrVC5 was closely related to qnrVC2
and qnrVC4, which corroborated the earlier findings (Fonseca
and Vicente, 2013). In addition to this, it was observed that
among all the qnrVC alleles listed out by Fonseca and Vicente,
(Fonseca and Vicente, 2013) qnrVC1, qnrVC3, and qnrVC6
alleles were associated with V. parahaemolyticus repeats (VPRs)
whereas qnrVC2, qnrVC4, and qnrVC5 alleles were associated
with VCRs, indicating different lineage for these two groups of
qnrVC alleles. Three dimensional structure prediction of QnrVC5
protein using I-TASSER server depicted the structure of a typical
PRP, threading into β helical folds interrupted by two loops
(Figure 1C). QnrVC5 protein encompassed 10 coils with two
loops (loop A and loop B) extending outward from the regular
structure, interrupting the β-helix turn. Loop A and loop B from
QnrVC5 shared 25 and 50% sequence homology, respectively,
with the corresponding loops of QnrB1. Structure predicted from
the threading experiments on I-TASSER server was based on
the templates of O-methyl transferase (PDB ID: 3DUL) from
Bacillus cereus and QnrB1 (PDB ID: 2XTY and 2XTW) from
K. pneumoniae. The structural analogs of the predicted structure
were QnrB1 (PDB ID: 2XTW), AhQnr (PDB ID: 3PSS) from
A. hydrophila and O-methyl transferase (PDB ID: 3DUL).
Contribution of qnrVC5 Gene in
Quinolone Resistance of their Native
V. fluvialis Host
The effect of qnrVC5 gene in elevating the MIC and MPC
of quinolones in V. fluvialis isolates was determined. All the
V. fluvialis isolates harboring qnrVC5 (BD146, L10734, and
L9978) were subjected to MIC assays with nalidixic acid,
norfloxacin, ciprofloxacin, and ofloxacin and MPC assays with
ciprofloxacin. Among these three strains, L9978 possessed
qnrVC5 as the only detected quinolone resistance determinant
whereas rest two were having other factors along with qnrVC5
gene (Table 1). V. fluvialis BD146 had GyrA S83I, ParC S85L
mutations and aac (6’)-Ib-cr gene as the quinolone resistance
factors in addition to qnrVC5 gene. V. fluvialis L10734 had GyrA
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TABLE 1 | Quinolone susceptibility of V. fluvialis strains and their corresponding E. coli transformants.
Strain/transformant Quinolone resistance
determinants
MIC (µg ml−1) MPC of Ciprofloxacin
(µg ml−1)
Nalidixic acid Norfloxacin Ciprofloxacin Ofloxacin
V. fluvialis
BD146 GyrA S83I, ParC S85L,
qnrVC5 and aac(6’)Ib-cr
1500 17.5–20 10 10 320
L15318 GyrA S83I, ParC S85L 1000 15 2.5–5 8 40
L10734 GyrA S83I, ParC S85L and
qnrVC5
125 10 2.5 8 40
L9978 qnrVC5 2 1.25 0.312 0.5 1.25–5
L13828 None 0.75 0.312 0.156 0.312 0.625–2.5
E. coli JM109
BD146 transformant (7.5 kb+) qnrVC5 and aac(6’)Ib-cr 400 4 0.5 1 ND
BD146 transformant (7.5 kb–) aac(6’)Ib-cr 200 2 0.25 0.5 ND
L10734 transformant qnrVC5 200 2 0.25 1 ND
L9978 transformant qnrVC5 400 4 0.5 2 ND
JM109 (non-transformant) None 50 1 0.125 0.5 ND
ND, Not done.
S83I and ParC S85L mutations along with qnrVC5 gene (Table 1).
The quinolone resistant V. fluvialis strain L15318 (having GyrA
S83I and ParC S85L mutations and lacking qnrVC5) and
quinolone sensitive V. fluvialis strain L13828 were included as
controls (Table 1). The MIC and MPC values of V. fluvialis
isolates for quinolones have been mentioned in Table 1. It was
observed that when compared to the sensitive strain L13828, the
qnrVC5-bearing strain L9978 showed about twofold to fourfold
elevation in MIC of tested quinolones and twofold elevation
in MPC of ciprofloxacin. When compared to L15318, BD146
showed twofold to fourfold increase in MIC of ciprofloxacin and
slight increase (<twofold) in MIC of nalidixic acid, norfloxacin,
and ofloxacin presumably due to additional presence of PMQR
determinants qnrVC5 gene and aac (6’)-Ib-cr gene apart from
GyrA and parC mutations. This result also indicated that qnrVC5
and aac (6’)-Ib-cr determinants may chiefly contribute toward
resistance to ciprofloxacin. As expected, the MPC of ciprofloxacin
was also elevated eightfold in V. fluvialis BD146 when compared
to L15318 and L10734. Though it may be difficult to compare
MIC/MPC of non-isogenic strains, synergy between different
resistance factors was evident in majority of cases except L10734
and L15318. Similarly, the lower MIC obtained for nalidixic acid
in L10734 as compared to L15318 could not be explained.
Contribution of qnrVC5 Gene in
Quinolone Resistance of E. coli
Transformants
In the previous studies from our laboratory, plasmid preparations
from V. fluvialis isolates BD146 (Rajpara et al., 2009), L10734,
and L9978 (Singh et al., 2012) were transformed into E. coli
JM109 to elucidate their transferable traits. E. coli transformants
of these three V. fluvialis plasmid preparations harboring qnrVC5
gene were utilized in this study to find the effect of this gene
in elevating the MIC of quinolones. For BD146, two types of
E. coli transformants were observed on the basis of presence or
absence of a 7.5 kb plasmid pBD146 harboring qnrVC5 gene.
The transformants that possessed 7.5 kb plasmid as well as
another low copy number plasmid [bearing aac(6’) Ib-cr gene]
were termed as 7.5 kb+. On the other hand, the transformants
harboring only low copy number plasmid but devoid of the 7.5 kb
plasmid were termed as 7.5 kb- (Rajpara et al., 2009). In other
words, the transformants 7.5 kb+ possessed both qnrVC5 and
aac(6’) Ib-cr genes whereas 7.5 kb- transformants were positive
for aac (6’) Ib-cr gene only (Table 1). Therefore, in the present
study, one 7.5 kb+ transformant was selected to study the effect
of qnrVC5 gene in combination with aac (6’) Ib-cr and one 7.5 kb-
transformant was selected to study the effect of aac (6’) Ib-cr alone
in quinolone resistance. For similar reasons, transformants of
L10734 and L9978 bearing qnrVC5 gene (Singh et al., 2012) were
included to study the effect of qnrVC5 gene alone. Untransformed
E. coli JM109 was used as a negative control for the MIC
assays. The MIC values for all the four transformants and E. coli
JM109 are mentioned in Table 1. The transformants having
qnrVC5 alone showed twofold to fourfold elevation in MIC of
norfloxacin, ciprofloxacin and ofloxacin and fourfold to eightfold
increase in the MIC of nalidixic acid when compared to E. coli
JM109. The 7.5 kb+ transformant having qnrVC5 along with
aac (6’) Ib-cr gene showed eightfold increase in MIC of nalidixic
acid and fourfold for norfloxacin and ciprofloxacin. The 7.5 kb+
transformant showed twofold increase in the MIC of ofloxacin.
The 7.5 kb- transformant having aac (6’) Ib-cr gene alone, showed
fourfold increase in MIC for nalidixic acid and twofold for
norfloxacin and ciprofloxacin but did not show any effect against
ofloxacin.
Expression of qnrVC5 Gene in Native
V. fluvialis Host and E. coli Transformants
RT-PCR was carried out to confirm the expression of qnrVC5
gene and aac(6’) Ib-cr gene in the native host and their E. coli
transformants (Figure 2). In both the cases, genes were expressed
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FIGURE 2 | Expression of qnrVC5 and aac(6’) Ib-cr genes in the native
V. fluvialis host and in E. coli JM109 transformants derived from the
plasmids of native hosts. 100 bp Gene ruler (Fermentas) was used as the
marker (M). Lane 1: Negative control (without reverse transcription step) for
RT-PCR product of qnrVC5 transcript (657 bp) from V. fluvialis hosts BD146;
Lanes 2 to 4: RT-PCR products of qnrVC5 transcript (657 bp) from V. fluvialis
hosts BD146, L10734 and L9978, respectively; Lanes 5 to 7: RT-PCR
products of qnrVC5 transcript (657 bp) from transformants of BD146
(7.5 kb+), L10734 and L9978; Lane 8: Negative control (without reverse
transcription step) for RT-PCR product of aac(6’) Ib-cr transcript (657 bp) from
V. fluvialis hosts BD146; Lanes 9 to 11: RT-PCR products of aac(6’) Ib-cr
transcript (608 bp) from V. fluvialis BD146 and its transformants (7.5 kb+ and
7.5 kb–), respectively.
with the expected band size of 657 bp for qnrVC5 (Figure 2, Lanes
2 to 7) and 608 bp for aac(6’) Ib-cr (Figure 2, Lanes 9 to 11).
The negative controls without reverse transcription step that were
included to ensure the absence of DNA contamination in RNA
templates, did not show any band corresponding to the expressed
genes. Two such negative controls with BD146 RNA templates for
RT-PCR of qnrVC5 and aac(6’) Ib-cr transcripts have been shown
(Figure 2, Lanes 1 and 8, respectively).
Effect of PNA Against qnrVC5 Gene in
Native V. fluvialis Host
Once the presence of qnrVC5 RNA was confirmed in the native
host, a peptide-PNA against qnrVC5 RNA was used to silence
its expression. MIC of ciprofloxacin for V. fluvialis BD146
was determined in the presence of increasing concentrations
of PNA (0, 2, 4, and 6 µM). The results showed a steady
decrease of MIC values with increasing concentration of PNA
with 4 µM of PNA appearing as an effective dose for inhibition.
Subsequently, MIC of ciprofloxacin for all the three qnrVC5-
bearing V. fluvialis isolates (BD146, L10734, and L9978) and one
qnrVC5-lacking V. fluvialis isolate L15318 was tested at a final
concentration of 4 µM of PNA. Twofold to eightfold decrease
in MIC of ciprofloxacin in all the three isolates was observed in
the presence of PNA when compared to the control with no PNA
(Table 2). In qnrVC5-lacking V. fluvialis isolate L15318, the MIC
of ciprofloxacin was similar irrespective of the presence of PNA
indicating that PNA did not have any non-specific inhibitory
activity (Table 2).
Gene Cloning and Recombinant Protein
Expression
The qnrVC5 gene was cloned in pET28a expression vector
and the authenticity of the recombinant clones was confirmed.
A protein band of ∼27 kDa was found to be overexpressed by
the recombinants on 1 mM IPTG induction. This protein band
was excised from the SDS-PAGE gel and subjected to trypsin
digestion. The peptide mass fingerprinting analysis confirmed it
to be QnrVC5.
Elevation of MIC for quinolones in
qnrVC5 Recombinants
Minimum inhibitory concentration assays were carried out
to study the functionality of recombinant QnrVC5 protein.
MIC was tested with different generations of quinolones
with nalidixic acid representing first generation, norfloxacin,
ciprofloxacin, ofloxacin, and levofloxacin representing second
generation, sparfloxacin for third generation and moxifloxacin as
a representative of fourth generation. Interestingly, recombinant
E. coli BL21(λDE3) cells were found to show eightfold to
more than 64-fold increase in MIC of different quinolones
when compared to control having pET28a alone (Table 3).
QnrVC5 conferred higher resistance toward ciprofloxacin and
sparfloxacin as the MICs of these two drugs were elevated to more
than 64-fold. MIC of levofloxacin and moxifloxacin were elevated
to 64-fold and 32-fold, respectively. QnrVC5 elevated the MIC of
both norfloxacin and ofloxacin to 16-fold and nalidixic acid to
eightfold (Table 3).
DISCUSSION
In the studies aimed at unraveling the molecular mechanisms
of drug resistance in the clinical isolates of V. fluvialis, a new
allele named qnrVC5 was reported from this laboratory (Rajpara
et al., 2009; Singh et al., 2012). The current study was intended
to characterize this plasmid-associated gene from those clinical
isolates, for its role in conferring protection/resistance toward
quinolones. qnrVC5 ORF was found as a gene cassette with its
TABLE 2 | Silencing effect of qnrVC5 gene in V. fluvialis strains.
V. fluvialis MIC of Ciprofloxacin (µg ml−1) Fold in reduction of MIC
PNA− PNA+
BD146 10–20 2.5–5 2–8
L10734 2.5 1.25 2
L9978 0.156 0.078 2
L15318 5 5 0
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TABLE 3 | MIC of quinolones for pET-qnrVC5 clone.
Quinolones MIC (µg ml−1) Fold in elevation of MIC
E. coli (BL21 λDE3) (pET-qnrVC5 clone) E. coli (BL21 λDE3) (pET28a)
Nalidixic acid 5 0.625 8
Norfloxacin 0.125 0.0078 16
Ciprofloxacin 0.0156 <0.000243 >64
Ofloxacin 0.0625 0.0039 16
Levofloxacin 0.0312 0.000487 64
Sparfloxacin 0.125 <0.00195 >64
Moxifloxacin 0.125 0.0039 32
own promoter with canonical sequence and attC site which was
identical to V. cholerae repeats (VCR). BLAST search indicated
that this gene cassette showed 99% identity with qnrVC2 gene
cassette found in the plasmid pVN84 harbored by V. cholerae
O1, isolated from Vietnam during 2004 as well as qnrVC5 gene
cassette found in another plasmid present in V. parahaemolyticus
V110, isolated from Hong Kong during 2010. The qnrVC5 gene
cassette also showed 99% identity to qnrVC4 gene cassettes
carried in class I integrons of Aeromonas caviae, A. hydrophila,
E. coli, and Salmonella enterica and 98% identity to qnrVC4 gene
in class I integron of A. punctata. This indicated evolutionary
relationship among qnrVC2, qnrVC5, and qnrVC4 gene cassettes
and their dissemination in various species of bacteria through
mobile genetic elements. qnrVC5 gene cassette showed 97%
homology with a qnr cassette found in super integron (SI)
on the small chromosome of V. cholerae MS6 (Okada et al.,
2014). The VCR region downstream of qnrVC5 ORF, showed
identity to the stretch of sequences present in the chromosome
of various Vibrio and Shewanella species. This indicated the
possible exchange of various resistance conferring genes or
gene cassettes among these bacterial species of Shewanellaceae
and Vibrionaceae families in their environmental vicinity. This
observation supported the hypothesis by Poirel et al. (2005a,b)
that these two families could be the reservoirs of qnr genes. This
additionally supported the chromosomal origin of qnr alleles. The
presence of regulatory motif for DNA-binding proteins PurR and
ArgR indicated the possible involvement of these elements in
controlling the expression of qnrVC5 gene. This was suggestive
of the probable biological function of Qnr proteins in relation to
purine and arginine metabolism or indicate that qnrVC5 might
be one of the potentially co-regulated set of genes interlinked with
amino acid and nucleotide metabolism.
The antimicrobial susceptibility assays clearly showed the
involvement of qnrVC5 gene in conferring resistance to different
quinolones. Compared to the sensitive V. fluvialis strain
(L13828), qnrVC5-bearing-isolates resisted the quinolone action
by virtue of qnrVC5 alone as in L9978 or in unison with other
mechanisms as in BD146 and L10734. The qnrVC5- bearing-
plasmids from the parent strain, transformed to the heterologous
host E. coli JM109, proved the role played by the gene in
reducing susceptibility toward quinolones. Hence, the qnrVC5
gene could effectively express its traits in different bacterial hosts
as these plasmids disseminated through horizontal gene transfer.
Silencing of the gene increased the susceptibility of the parent
strains toward ciprofloxacin from twofold to eightfold, again
confirming the role of qnrVC5 in drug resistance.
The results of MIC and MPC assays were vivid representations
of synergy between various quinolone resistance determinants
(with some exceptions) with BD146 as a carrier of all the
three determinants and rest of the isolates as carriers of either
one or two determinants. These results also clearly indicated
the major role of topoisomerase mutations in susceptibility for
quinolones with qnrVC5 or aac (6’)Ib-cr, playing the role of an
apprentice. Though the level of resistance conferred by qnrVC5
for ciprofloxacin was low, it apparently helped the pathogen
in elevating the MIC and MPC of ciprofloxacin for V. fluvialis
strains (BD146 and L9978) thus extending the mutant selection
window for ciprofloxacin in these strains. This is likely to help in
the selection of more mutants at higher concentrations of drug,
by enhancing the survival ability of the pathogen (Strahilevitz
et al., 2009). However, as described in the results section, there
were anomalies in this synergistic design and therefore could not
be explained. Perhaps, comparisons of susceptibility trends in
non-isogenic strains may not be very straight-forward and may
reflect a complex interplay of many known and yet unknown
genetic factors.
Recently, the role of qnrVC1 gene located in a chromosomal
integron in clinical and environmental Pseudomonas aeruginosa
isolates, in conferring resistance to quinolones, has been
described (Belotti et al., 2015). qnrVC1 gene with its promoter
was cloned in E. coli and P. aeruginosa and shown to confer
variable resistance to quinolones. In the present study, T7
promoter-based overexpression of qnrVC5 gene was utilized to
study the gene function in isolation which was not possible
in native V. fluvialis isolates. MIC study with the recombinant
reflected that the potency of this gene in conferring resistance
is significant and variable resistance was observed for different
generations of quinolones.
Using I-TASSER server, structure of QnrVC5 protein
was predicted and was found to be similar to that of
QnrB1 (Vetting et al., 2011) and AhQnr structure (Xiong
et al., 2011) implying that the function of QnrVC5 could
also be similar to the above two proteins (i.e., imparting
quinolone resistance). The important feature in the structures
of QnrB1 and AhQnr is the presence of two loops and their
contribution in protection of DNA gyrase from quinolones
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(Vetting et al., 2011; Xiong et al., 2011). Therefore, the
working model of Qnr proteins (PRPs with loops) in quinolone
resistance was proposed, in which the Qnr proteins disturb the
quinolone-topoisomerase-DNA complex (Vetting et al., 2011;
Xiong et al., 2011). Our functional analysis of recombinant
QnrVC5 protein also strengthened the above mentioned
model. QnrVC5 protein was shown to elevate the MIC of
different quinolones by varying degrees. The possible reason
for varied elevation in MIC would be the consequence
of varying binding orientations of the different quinolones
with the topoisomerase-DNA complex. For example, the
interactions of nalidixic acid and ciprofloxacin with gyrase
differ in drug binding orientation (perhaps reflected in
differences in their potency) such that Qnr destabilizes the
ciprofloxacin interaction to a greater extent than the nalidixic
acid interaction.
CONCLUSION
These findings prove that the carriage of qnrVC alleles on various
mobile genetic elements such as plasmids, integrons, and SXT
elements in a variety of organisms of different genera have been
disseminating quinolone resistance widely throughout the globe
(Fonseca et al., 2008; Rajpara et al., 2009; Kim et al., 2010;
Kumar and Thomas, 2011; Fonseca and Vicente, 2013). With
the indiscriminate use of quinolones, this can turn out to be
both a reason as well as a consequence of the serious problem
of multi-drug resistance.
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